“It was a difficult year, but we managed to grow. We sell 90% of production abroad”, Attila Santa, the company’s general manager, told ZF.
Santa SA company, which operates the Brasov drug plant, filed for insolvency in October 2019. “We are trying to exit insolvency as fast as possible. We are further diversifying generics offer, adding two-three products annually. We expect a 25% turnover increase in 2021”.
At present, the plant has 275 employees.
In line with finance ministry data, the company in 2020 posted RON233,000 profit from RON184,000 in 2019.
“At present, the plan operates at 25% of production capacity. We’re reached three production lines and we plan to have six lines overall”.
The two entrepreneurs of Brasov also control Sanosan Pharmaceuticals, with turnover of RON10 million in 2019.
(English version by Catalina Apostoiu)